TRAWS PHARMA INC (TRAW)
US68232V8019 - Common Stock
Overall TRAW gets a fundamental rating of 2 out of 10. We evaluated TRAW against 196 industry peers in the Pharmaceuticals industry. While TRAW seems to be doing ok healthwise, there are quite some concerns on its profitability. TRAW has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year TRAW has reported negative net income.
In the past year TRAW has reported a negative cash flow from operations.
TRAW had negative earnings in each of the past 5 years.
TRAW had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of TRAW (-733.43%) is worse than 98.46% of its industry peers.
TRAW's Return On Equity of -2247.07% is on the low side compared to the rest of the industry. TRAW is outperformed by 85.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -733.43% | ||
| ROE | -2247.07% | ||
| ROIC | N/A |
ROA(3y)-53.61%
ROA(5y)N/A
ROE(3y)-93.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TRAW does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRAW has more shares outstanding
There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
TRAW has an Altman-Z score of -69.15. This is a bad value and indicates that TRAW is not financially healthy and even has some risk of bankruptcy.
TRAW's Altman-Z score of -69.15 is on the low side compared to the rest of the industry. TRAW is outperformed by 94.36% of its industry peers.
TRAW has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -69.15 |
ROIC/WACCN/A
WACC9.06%
2.3 Liquidity
A Current Ratio of 1.88 indicates that TRAW should not have too much problems paying its short term obligations.
TRAW's Current ratio of 1.88 is on the low side compared to the rest of the industry. TRAW is outperformed by 69.23% of its industry peers.
A Quick Ratio of 1.88 indicates that TRAW should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.88, TRAW is not doing good in the industry: 62.56% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
TRAW shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.10%.
TRAW shows a decrease in Revenue. In the last year, the revenue decreased by 0.00%.
EPS 1Y (TTM)1.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2301.64%
Revenue 1Y (TTM)0%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%
3.2 Future
Based on estimates for the next years, TRAW will show a small growth in Earnings Per Share. The EPS will grow by 2.66% on average per year.
TRAW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.69% yearly.
EPS Next Y-356.73%
EPS Next 2Y-6.28%
EPS Next 3Y2.66%
EPS Next 5YN/A
Revenue Next Year1.55%
Revenue Next 2Y-9.42%
Revenue Next 3Y11.69%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TRAW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRAW. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.28%
EPS Next 3Y2.66%
5. Dividend
5.1 Amount
No dividends for TRAW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRAWS PHARMA INC
NASDAQ:TRAW (9/6/2024, 8:00:02 PM)
After market: 0.3502 -0.01 (-3.26%)0.362
+0.01 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.16M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -733.43% | ||
| ROE | -2247.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)1.1%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-356.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y